

MAIL DATE CANCEL

EX-569/1653

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Llinas-Brunet, M. et al
Appln. No. 09/368,670
Filed: 08/05/1999
For: Hepatitis C Inhibitor Peptides
Atty. Docket No. 13/063-2-C2

Group Art Unit: 1653
Examiner: D. Lukton

Box Sequence
U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

RECEIVED

JAN 07 2003

TECH CENTER 1600/2900

STATEMENT UNDER 37 CFR § 1.821(f)


Sir:

In response to the Communication dated December 20, 2002, setting a one month period for response, a new computer readable form (CRF) Sequence Listing is submitted herewith.

I hereby certify that:

The new computer readable form (CRF) Sequence Listing submitted herewith is identical to the paper Sequence Listing submitted on November 14, 2001.

Respectfully submitted,



Philip I. Datlow
Attorney for Applicant(s)
Reg. No. 41,482

Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4542

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Box Sequence
U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

on December 31, 2001

By: 
Philip I. Datlow
Reg. No. 41,482